Abstract: Disclosed are 13C and 15N derivatization reagents and their use for gas chromatography-mass spectroscopy and liquid chromatography/mass spectroscopy chemical identification and quantification.

Abstract: Disclosed are 13C and 15N derivatization reagents and their use for gas chromatography-mass spectroscopy and liquid chromatography/mass spectroscopy chemical identification and quantification.

Abstract: Disclosed are methods and systems for identifying biochemical changes in a subject in response to administration of a multi-component therapeutic and one or more active ingredients in the multi-component therapeutic. The methods and systems of the invention may be used to elucidate the interaction of the biological system's genome with its environments, and in the pharmacokinetic, pharmacodynamic and toxicology analysis of multi-component therapeutics. The metabolomics methods and systems of the invention can also be used in studies of plant derived agents to demonstrate biochemical alterations in response to the dynamic multi-component intervention.

Abstract: Embodiments of the present invention provide methods of assessing metabolite biomarkers to diagnose, monitor, prognose and treat colorectal cancer, as well as kits and systems in use thereof. In some embodiments, the metabolite biomarker profile of an subject suspected of having colorectal cancer may be compared to the metabolite biomarker profile of a healthy subject to determine if there are differences between the profiles indicative of colorectal cancer. In some embodiments, the stage of a subject's colorectal cancer may be determined. In certain embodiments, the metabolite biomarker profile of an subject may be useful in determining method of treatment for colorectal cancer. In other embodiments, the metabolite biomarker profiles of an subject having colorectal cancer may be compared prior to and after treatment to determine if there are differences between the profiles indicative of decreased colorectal cancer morbidity.